Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | 147 Hamelin St WINNIPEG MB R3T 3Z1 |
Tel: | N/A |
Website: | N/A |
IR: | N/A |
Key People | ||
Leslie L. Dan Executive Chairman of the Board | Stephen A. Hurly President, Chief Executive Officer, Director | Erick J. Lucera Chief Financial Officer, Treasurer, Secretary |
Glen C. MacDonald Chief Scientific Officer | Gregory P. Adams Chief Development Officer | Arthur P. DeCillis Chief Medical Officer |
Business Overview |
Viventia Bio Inc is a Canada-based biological company. The Company is a biologics oncology company focused on designing, engineering and developing targeted protein therapeutics. The Company's advanced product candidates, Vicinium and Proxinium, are locally administered TPTs. The Company is engaged in developing next generation oncology therapeutics utilizing the Targeted Protein Therapeutic technology (TPT). The TPTs has been designed to overcome the efficacy and safety challenges of existing antibody-drug conjugates. The Company is engaged in designing, engineering, developing and commercializing TPTs to identify and address patients with cancers that has a high unmet medical needs. |
Financial Overview |
For the six months ended 30 June 2015, Viventia Bio Inc revenues was not reported. Net loss increased 31% to $4.9M. Higher net loss reflects Research and development increase of 52% to $2.8M (expense), Interest Exp-Net of Capitalized Interest increase of 95% to $286K (expense), General and administrative increase of 3% to $1.8M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.29 to -$0.38. |